Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Tightens Drug Pricing Message, But Loose Ends Remain

Executive Summary

Drug makers are under increasing pressure regarding the cost of their medicines, but instead of pointing fingers at payers for patients' out-of-pocket costs, the industry has shifted to a more collaborative tone, although some tensions will take time to overcome.

You may also be interested in...



Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth

Lilly’s new CEO David Ricks said he had confidence in the Trump Administration’s ability to understand and respond to the biopharma industry’s needs as well as address drug pricing concerns. The company’s fourth quarter earnings could insulate it from cost criticism, since sales volume drove revenue gains, not prices.

2Q Pharma Results Preview: What Lies Ahead

The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.

BIO 2016 Notebook: Pricing And Innovation Hot Topics In San Francisco

Scrip spoke with several executives and attended multiple panel discussions in San Francisco during the first full day of BIO's annual international gathering. Drug pricing and enabling innovation emerged as key themes.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141925

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel